FMP

FMP

Enter

KPRX - Kiora Pharmaceutical...

Financial Summary of Kiora Pharmaceuticals, Inc.(KPRX), Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commerc

photo-url-https://financialmodelingprep.com/image-stock/KPRX.png

Kiora Pharmaceuticals, Inc.

KPRX

NASDAQ

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.

0.506 USD

-0.0312 (-6.16%)

About

ceo

Dr. Brian M. Strem Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.kiorapharma.com

exchange

NASDAQ

Description

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patient...

CIK

0001372514

ISIN

US49721T3095

CUSIP

49721T101

Address

1371 East 2100 South

Phone

781 788 8869

Country

US

Employee

12

IPO Date

Feb 13, 2015

Summary

CIK

0001372514

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

49721T101

ISIN

US49721T3095

Country

US

Price

0.51

Beta

-0.26

Volume Avg.

1.68M

Market Cap

13.29M

Shares

-

52-Week

0.462-5.25

DCF

0.48

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.19

P/B

-

Website

https://www.kiorapharma.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest KPRX News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep